Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 1896-1918
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1896
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.1896
Table 6 Summary of ongoing clinical trials evaluating combination therapy of immune checkpoint inhibitors with locoregional therapies
BCLC stage | Estimated/included patients | Clinical trial identifier | Phase | Arm |
0 | 530 | NCT03383458 | III | Arm 1: RFA/MWA/curative resection + nivolumab (neoadjuvant) vs Arm 2: RFA/MWA/curative resection |
B | 26 | NCT03397654 (PETAL) | Ib | Single arm: TACE followed by pembrolizumab |
B | 950 | NCT04246177 LEAP-012 | III | Arm 1: TACE + lenvatinib + pembrolizumab vs Arm 2: TACE |
B | 49 | NCT03572582 (IMMUTACE) | II | Single arm: TACE + Nivolumab |
B | 522 | NCT04268888 TACE-3 | II/III | Arm 1: DEB-TACE + Nivolumab vs Arm 2: DEB-TACE |
B | 765 | NCT04340193, CheckMate 74W | III | Arm 1: TACE + nivolumab + ipilimumab vs Arm 2: TACE + nivolumab + placebo |
A | 50 | NCT03939975 | II | Single arm: Pembrolizumab or nivolumab or toripalimab. For participants with stable disease or atypical progression to immunotherapy therapy, RFA or MWA is performed additionally |
B | 130 | NCT03864211 | I/II | Single arm: RFA or MWA followed by Toripalimab |
B | 61 | NCT01853618 | I/II | Single arm: Tremelimumab + RFA or TACE |
B | 30 | NCT03638141 | II | Single arm: Initial DEB-TACE followed by Durvalumab + tremelimumab |
B | 22 | NCT03937830 | II | Single arm: Durvalumab and bevacizumab + TACE |
B/C | 600 | NCT03778957 EMERALD-1 | III | Arm 1: TACE + durvalumab vs Arm 2: TACE +bevacizumab + durvalumab |
A/B | 662 | NCT04102098 IMbrave050 | III | Atezolizumab plus bevacizumab in HCC patients at high risk of recurrence after surgical resection or ablation vs Active surveillance in HCC patients at high risk of recurrence after surgical resection or ablation |
- Citation: Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? World J Gastrointest Oncol 2021; 13(12): 1896-1918
- URL: https://www.wjgnet.com/1948-5204/full/v13/i12/1896.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.1896